WUXI XDC THE BIOCONJUGATION LEADER

Serial Number 97975831
Registration 7116996
700

Registration Progress

Application Filed
Sep 18, 2021
Under Examination
Nov 8, 2022
Approved for Publication
Sep 13, 2022
Published for Opposition
Sep 13, 2022
Registered
Jul 18, 2023

Trademark Image

WUXI XDC THE BIOCONJUGATION LEADER

Basic Information

Serial Number
97975831
Registration Number
7116996
Filing Date
September 18, 2021
Registration Date
July 18, 2023
Published for Opposition
September 13, 2022
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 18, 2023
Registration
Registered
Classes
040 042

Rights Holder

WuXi XDC Cayman Inc.

03
Address
No.11, Xinhui Ring Road
Xinwu District
Wuxi, Jiangsu Province 214028
CN

Ownership History

WuXi XDC Cayman Inc.

Original Applicant
03
Wuxi, Jiangsu Province CN

WuXi XDC Cayman Inc.

Owner at Publication
03
Wuxi, Jiangsu Province CN

WuXi XDC Cayman Inc.

Original Registrant
03
Wuxi, Jiangsu Province CN

Legal Representation

Attorney
Eric Lamb

USPTO Deadlines

Next Deadline
1304 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230718)
Due Date
July 18, 2029
Grace Period Ends
January 18, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description Documents
Jul 18, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jul 18, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 16, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jun 15, 2023 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Jun 15, 2023 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Jun 9, 2023 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Jun 9, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jun 8, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jun 2, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jun 1, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 5, 2023 IUAF S USE AMENDMENT FILED Loading...
Jun 1, 2023 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
May 5, 2023 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
May 30, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 5, 2023 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
May 5, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 8, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 13, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 13, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 24, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 9, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 28, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jun 28, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jun 28, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jun 28, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jun 22, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 23, 2021 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Oct 22, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 22, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 040
Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates
First Use Anywhere: 20210700
First Use in Commerce: 20210900
Class 042
Development of products for others; pharmaceutical drug development services; research and development of new products; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates
First Use Anywhere: 20210700
First Use in Commerce: 20210900

Additional Information

Design Mark
The mark consists of the stylized wordings "WUXI" over "XDC", partially inside an incomplete oval outline that intersects with another incomplete oval outline. Below these appears the wording "THE BIOCONJUGATION LEADER" in stylized font.

Classification

International Classes
040 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"WUXI" OR "BIOCONJUGATION"